Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to voluntarily take part in clinical research.
- People who are 18 years of age or older.
- People whose general health and ability to carry out daily activities meets a standard scoring level of 0–2 on a recognised cancer performance scale (confirm with trial site).
- People who have been diagnosed with multiple myeloma (MM) based on established international diagnostic guidelines.
- People whose multiple myeloma can be measured through tests and scans.
- People who have previously been treated with three specific types of myeloma therapy: a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a CD38 monoclonal antibody (confirm with trial site for specific drug names).
- People who have had at least three prior lines of treatment for multiple myeloma, with at least one full treatment cycle completed in each line (unless the treatment caused the disease to get worse).
- People whose expected survival is at least 3 months.
- People whose blood and other lab test results from the screening period fall within the required ranges (confirm with trial site).
Who may not be able to join:
- People who have previously received treatment that specifically targeted a protein called FcRH5.
- People who have received certain prior cancer treatments that meet specific exclusion conditions before a cell collection procedure called apheresis (confirm with trial site).
- People who have been diagnosed with plasma cell leukaemia, Waldenström macroglobulinaemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
- People who test positive for hepatitis B surface antigen, hepatitis B virus DNA, hepatitis C antibodies, hepatitis C virus RNA, or HIV antibodies.
- People with a known history of serious allergic reactions, severe sensitivity reactions, or intolerance to the ingredients used in CAR-T cell therapies, including a substance called DMSO.
- People who have serious underlying health conditions.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study or within one year of receiving the study treatment.
- People who are currently enrolled in another clinical trial at the same time.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lugui Qiu, MD, Institute of Hematology & Blood Diseases Hospital, China
Phone: +86 18618260033
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT) rate.; Incidence, severity, and type of treatment-emergent adverse events (TEAEs); To determine the recommended dose for phase II clinical trials (RP2D); Maximum concentration (Cmax); Time to Cmax; Time to the last observed concentration; Area Under the Curve (AUC) of the concentration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.